Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 47
Novo Nordisk's modern and new generation insulins have a
stable market position in the USA insulin market
USA fast-acting insulin
Segment volume
USA premix insulin
Segment volume
USA long-acting insulin
Segment volume
Levemir® share
NovoLogⓇ share
NovoLog® Mix 70/30 share
TresibaⓇ share
tMU
tMU
tMU
CAGR volume¹: 3.1%
80
MI penetration: 83.9%
100%
80
CAGR volume¹: (6.2%)
MI penetration: 52.0%
CAGR volume¹: 3.8%
100%
80
MI penetration: 73.7%
100%
70
70
70
80%
80%
80%
60
60
60
50
- 60%
50
60%
50
60%
40
40
40
40%
30
30
40%
30
40%
20
20
20
20%
20%
20%
10
10
10
0
0%
0%
0
0%
0
May
2013
May
2018
May
2013
May
May
May
2018
2013
2018
1 CAGR for 5-year period; tMU: Thousand mega units
Note: US trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, ie including human insulin
Source: IQVIA monthly MAT May, 2018 volume figures
changing
diabetes®
novo nordiskView entire presentation